'Teva will contribute circa 4.5% of Group EBITDA..."
Where did you get this metric? If you look at the initial acquisition announcement, they bought it for ~US$652m and said it was priced at less than 6 times EBITDA.
If you assume it's 6 times, then the forecast EBITDA should be ~US$108m, or AUD149m, assuming a 0.75 exchange rate.
FY16 'underlying' EBITDA was AUD88m.
So the Teva acquisition should contribute the majority of EBITDA, all else being equal.
(Of course, we know that due to Dofetilide, Fabior, Sorilux and greater MCS earnings, the FY16 EBITDA figure for the on-going business will be higher).
Ann: Investor Day - Presentation, page-3
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.71 |
Change
0.070(1.51%) |
Mkt cap ! $400.7M | |||
| Open | High | Low | Value | Volume |
| $4.67 | $4.75 | $4.62 | $953.1K | 203.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1236 | $4.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.72 | 620 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MYX (ASX) Chart |